BHV-7000 Open-Label Extension Bipolar Mania Study
A Phase 2, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of BHV-7000 in Treatment of Bipolar I Disorder
Sponsor: Biohaven Therapeutics Ltd.
Terminated
Business Decision
Listed as NCT06423794, this PHASE2 trial focuses on Bipolar Disorder and remains terminated or withdrawn. Sponsored by Biohaven Therapeutics Ltd., it has been updated 7 times since 2024, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Jan 2026 [monthly]
Terminated PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Terminated PHASE2
Status: Enrolling By Invitation → Terminated
-
Feb 2025 — Jul 2025 [monthly]
Enrolling By Invitation PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Enrolling By Invitation PHASE2
▶ Show 2 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE2
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Biohaven Therapeutics Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .